[HTML][HTML] The effects of post-translational modifications on alpha-synuclein aggregation and immune cell activation in Parkinson's disease
Z Khan, YJ Jung - Exploration of Neuroprotective Therapy, 2023 - explorationpub.com
Post-translational modifications (PTMs) of alpha-synuclein (α-syn) can alter protein
aggregation propensity to affect α-syn oligomer and fibril formation. The inflammatory …
aggregation propensity to affect α-syn oligomer and fibril formation. The inflammatory …
Abnormal modification of alpha-synuclein and its mechanism in Parkinson's disease
X Qi, J Li, Y Zhu, L Yu, P Wang - Chinese Journal of Tissue Engineering …, 2024 - cjter.com
BACKGROUND: The formation of Lewy bodies due to abnormal α-synuclein aggregation is
a characteristic pathological change in Parkinson's disease. In recent years, several studies …
a characteristic pathological change in Parkinson's disease. In recent years, several studies …
C2 神经酰胺对帕金森病模型鼠多巴胺能神经元的保护作用
李家慧， 齐雪， 朱远峰， 禹璐， 刘立峰， 王鹏 - 中国组织工程研究, 2024 - cjter.com
C2 神经酰胺对帕金森病模型鼠多巴胺能神经元的保护作用 Page 1 Chinese Journal of Tissue
Engineering Research|Vol 28|No.11|April 2024|1653 中国组织工程研究 Chinese Journal of …
Engineering Research|Vol 28|No.11|April 2024|1653 中国组织工程研究 Chinese Journal of …
Using cell lysates to assess N-terminal acetyltransferase activity and impairment
M Lundekvam, T Arnesen, N McTiernan - Methods in Enzymology, 2023 - Elsevier
The vast majority of eukaryotic proteins are subjected to N-terminal (Nt) acetylation. This
reaction is catalyzed by a group of N-terminal acetyltransferases (NATs), which co-or post …
reaction is catalyzed by a group of N-terminal acetyltransferases (NATs), which co-or post …
大脑外病理性α-突触核蛋白: 这么多种子离源泉这么近
Y Yang, Z Zhang - 中国神经再生研究(英文版), 2024 - sjzsyj.com.cn
α-突触核蛋白是一种主要存在于突触前末端的蛋白. 在包括帕金森病在内的多种神经退行性疾病
中, 已发现了α-突触核蛋白存在异常折叠和积聚. 聚集和高度磷酸化的α-突触核蛋白是大脑中 …
中, 已发现了α-突触核蛋白存在异常折叠和积聚. 聚集和高度磷酸化的α-突触核蛋白是大脑中 …
The N-terminal Region of alpha-Synuclein Controls Amyloid Nucleation at the Condensate Interface
RJ Thrush, DM Vadukul, SC Allerton, M Storch… - bioRxiv, 2024 - biorxiv.org
Alpha-Synuclein can self-assemble into amyloid fibrils in neurodegenerative diseases,
including Parkinson's disease. Recent studies show alpha-synuclein can undergo liquid …
including Parkinson's disease. Recent studies show alpha-synuclein can undergo liquid …
Alpha Synuclein Toxicity and Non-motor Parkinson's
GM Mazzotta, C Conte - 2024 - preprints.org
Parkinson's disease (PD) is a common multisystem neurodegenerative disorder affecting
1% of the population above 60 years. The main neuropathological features of PD are the …
1% of the population above 60 years. The main neuropathological features of PD are the …
Amiloidinių baltymų α-sinukleino ir S100A9 neurotoksinio poveikio mechanizmo mikroglijos ląstelėms tyrimas
J Gružaitė - 2024 - epubl.ktu.edu
Abstract [eng] Over the last few years, various studies have expanded our knowledge of the
molecular mechanisms underlying the pathogenesis of neurodegenerative diseases and …
molecular mechanisms underlying the pathogenesis of neurodegenerative diseases and …
Protective effect of C2 ceramide on dopaminergic neurons in a mouse model of Parkinson's disease
J Li, X Qi, Y Zhu, L Yu, L Liu, P Wang - Chinese Journal of Tissue …, 2024 - cjter.com
BACKGROUND: C2 ceramide reduces the formation of Alpha-Synuclein (α-Syn) oligomers
as the protein phosphatase 2A agonist, which has an important regulatory effect on cell …
as the protein phosphatase 2A agonist, which has an important regulatory effect on cell …